Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Lorenzo Guglielmetti^{1

2

3}, Gunar Günther^{4

5}, Claude Leu⁴, Daniela Cirillo⁶, Raquel Duarte^{7

8

9

10}, Alberto L Garcia-Basteiro^{11

12}, Delia Goletti¹³, Mateja Jankovic¹⁴, Liga Kuksa^{15

16}, Florian P Maurer^{17

18

19}, Frédéric Méchaï²⁰, Simon Tiberi^{21

22}, Frank van Leth^{23

24}, Nicolas Veziris^{2

25

26}, Christoph Lange^{19

27

28

29}; Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet)

Affiliations

¹ Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France lorenzo.guglielmetti@aphp.fr.
² APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.
³ APHP, Infectious Disease Unit, Avicenne Hospital, Bobigny, France.
⁴ Department of Pulmonology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁵ Department of Internal Medicine, School of Medicine, University of Namibia, Windhoek, Namibia.
⁶ WHO Collaborating Centre and TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milano, Italy.
⁷ Epidemiology Research Unit (EpiUnit), Institute of Public Health, University of Porto, Porto, Portugal.
⁸ Departamento de Ciências de Saúde Pública, Ciências Forenses e Educação Médica, Faculty of Medicine, University of Porto, Porto, Portugal.
⁹ Serviço de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
¹⁰ National Tuberculosis Program, Directorate-General of Health, Lisbon, Portugal.
¹¹ Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Moçambique.
¹² ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
¹³ National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy.
¹⁴ Clinic for Lung Diseases, University of Zagreb School of Medicine and University Hospital Center Zagreb, Zagreb, Croatia.
¹⁵ Riga East University Hospital, TB and Lung Disease Centre, Riga, Latvia.
¹⁶ Riga Stradins University, Riga, Latvia.
¹⁷ National and Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany.
¹⁸ Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁹ German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
²⁰ APHP, Infectious Disease Unit, Avicenne Hospital, Université Paris 13, IAME, INSERM, Bobigny, France.
²¹ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.
²² Royal London Hospital, Barts Health National Health Service Trust, London, UK.
²³ VU University, Department of Health Sciences, Amsterdam, The Netherlands.
²⁴ Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
²⁵ APHP, Groupe Hospitalier Universitaire Sorbonne Université, site Saint-Antoine, Département de bactériologie, Paris, France.
²⁶ Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France.
²⁷ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
²⁸ Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany.
²⁹ Baylor College of Medicine and Texas Childreńs Hospital, Global TB Program, Houston, TX, USA.

PMID: 35589114
PMCID: PMC9186306
DOI: 10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Lorenzo Guglielmetti et al. Eur Respir J. 2022.

. 2022 May 19;59(5):2200388.

doi: 10.1183/13993003.00388-2022. Print 2022 May.

Authors

Affiliations

¹ Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France lorenzo.guglielmetti@aphp.fr.
² APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.
³ APHP, Infectious Disease Unit, Avicenne Hospital, Bobigny, France.
⁴ Department of Pulmonology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
⁵ Department of Internal Medicine, School of Medicine, University of Namibia, Windhoek, Namibia.
⁶ WHO Collaborating Centre and TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milano, Italy.
⁷ Epidemiology Research Unit (EpiUnit), Institute of Public Health, University of Porto, Porto, Portugal.
⁸ Departamento de Ciências de Saúde Pública, Ciências Forenses e Educação Médica, Faculty of Medicine, University of Porto, Porto, Portugal.
⁹ Serviço de Pneumologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
¹⁰ National Tuberculosis Program, Directorate-General of Health, Lisbon, Portugal.
¹¹ Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Moçambique.
¹² ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
¹³ National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy.
¹⁴ Clinic for Lung Diseases, University of Zagreb School of Medicine and University Hospital Center Zagreb, Zagreb, Croatia.
¹⁵ Riga East University Hospital, TB and Lung Disease Centre, Riga, Latvia.
¹⁶ Riga Stradins University, Riga, Latvia.
¹⁷ National and Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany.
¹⁸ Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁹ German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
²⁰ APHP, Infectious Disease Unit, Avicenne Hospital, Université Paris 13, IAME, INSERM, Bobigny, France.
²¹ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.
²² Royal London Hospital, Barts Health National Health Service Trust, London, UK.
²³ VU University, Department of Health Sciences, Amsterdam, The Netherlands.
²⁴ Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
²⁵ APHP, Groupe Hospitalier Universitaire Sorbonne Université, site Saint-Antoine, Département de bactériologie, Paris, France.
²⁶ Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France.
²⁷ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
²⁸ Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany.
²⁹ Baylor College of Medicine and Texas Childreńs Hospital, Global TB Program, Houston, TX, USA.

PMID: 35589114
PMCID: PMC9186306
DOI: 10.1183/13993003.00388-2022

Abstract

Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination https://bit.ly/3jz85eh

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: L. Guglielmetti is the co-principal investigator of two MSF-sponsored clinical trials testing shorter MDR-TB regimens, and has no other competing interests to disclose. All other authors have no competing interests.

Comment in

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
Masini T, Kanchar A, Mirzayev F, Viney K, Yedilbayev A, Zignol M, Falzon D. Masini T, et al. Eur Respir J. 2022 Aug 25;60(2):2201227. doi: 10.1183/13993003.01227-2022. Print 2022 Aug. Eur Respir J. 2022. PMID: 35777762 Free PMC article.

References

1. Lange C, Kay A, Mandalakas AM. The need for effective drugs for TB prevention: set your goals high, and don't stop till you get there. Int J Tuberc Lung Dis 2022; 26: 85–88. doi:10.5588/ijtld.21.0736 - DOI - PMC - PubMed
1. Njie GJ, Morris SB, Woodruff RY, et al. . Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med 2018; 55: 244–252. doi:10.1016/j.amepre.2018.04.030 - DOI - PMC - PubMed
1. World Health Organization . WHO Consolidated Guidelines on Tuberculosis. Module 1: Prevention – Tuberculosis Preventive Treatment. Geneva, World Health Organization, 2020. - PubMed
1. Swindells S, Ramchandani R, Gupta A, et al. . One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med 2019; 380: 1001–1011. doi:10.1056/NEJMoa1806808 - DOI - PMC - PubMed
1. Dorman SE, Nahid P, Kurbatova EV, et al. . Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 2021; 384: 1705–1718. doi:10.1056/NEJMoa2033400 - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Affiliations

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Authors

Affiliations

Abstract

Conflict of interest statement

Comment in

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous